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Abstract
Summary Patient information is important to help patients fully participate in their healthcare. Commonly accessed osteoporosis
patient information resources were identified and assessed for readability, quality, accuracy and consistency. Resources
contained inconsistencies and scored low when assessed for quality and readability. We recommend optimal language and
identify information gaps to address.
Introduction The purpose of this paper is to identify commonly accessed patient information resources about osteoporosis and
osteoporosis drug treatment, appraise the quality and make recommendations for improvement.
Methods Patient information resources were purposively sampled and text extracted. Data extracts underwent assessment of readability
(Flesch Reading Ease and Flesch-Kincaid Grade Level) and quality (modified International Patient Decision Aid Standards (m-
IPDAS)). A thematic analysis was conducted, and keywords and phrases were used to describe osteoporosis and its treatment identified.
Findings were presented to a stakeholder group who identified inaccuracies and contradictions and discussed optimal language.
Results Nine patient information resources were selected, including webpages, a video and booklets (available online), from
government, charity and private healthcare providers. No resource met acceptable readability scores for both measures of
osteoporosis information and drug information. Quality scores from the modified IPDAS ranged from 21 to 64% (7–21/33).
Thematic analysis was informed by Leventhal’s Common-Sense Model of Disease. Thirteen subthemes relating to the identity,
causes, timeline, consequences and controllability of osteoporosis were identified. Phrases and words from 9 subthemes were
presented to the stakeholder group who identified a predominance of medical technical language, misleading terms about
osteoporotic bone and treatment benefits, and contradictions about symptoms. They recommended key descriptors for providers
to use to describe osteoporosis and treatment benefits.
Conclusions This study found that commonly accessed patient information resources about osteoporosis have highly variable
quality, scored poorly on readability assessments and contained inconsistencies and inaccuracies. We produced practical recom-
mendations for information providers to support improvements in understanding, relevance, balance and bias, and to address
information gaps.
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Introduction
Government policy in the UK places emphasis on providing
patients with good quality health information to encourage
patient participation in their healthcare, by supporting the in-
volvement of patients in their care and treatment decision-
making processes [1]. Improving access to quality information
is rated as a top research priority for people living with oste-
oporosis [2]. The internet is increasingly becoming an influ-
ential source of health care information [3], with as many as
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61% of UK patients accessing medical information via the
web [4]. A wide range of providers may offer patient infor-
mation resource online, with government, charity and private
healthcare stakeholders being perceived as more credible than
other sources [5]; however, the quality of these resources, in
the case of osteoporosis, is unknown.
The quality of patient information encompasses a range of
issues including accuracy and comprehensiveness, accessibil-
ity, acceptability, presentation style, comprehensibility, rele-
vance and utility and attention to health literacy [6].
Comprehensiveness relates to the appropriate range of issues
that need to be covered [7]; it is important that patient infor-
mation presents an accurate, comprehensive coverage of a
subject for example, discussing benefits and harms of treat-
ment in equal detail, in order to give a balanced ac-
count [8]. The current ‘osteoporosis crisis’, characterised
by poor treatment uptake and the consequent levels of
preventable fracture has been blamed on health profes-
sionals’ failure to clearly communicate these aspects of
osteoporosis drug treatment to patients [9].
The ease with which patient information is understandable
or comprehensible will be influenced by a range of factors
such as the way information is presented, the language used
and the health literacy of the reader. Health literacy is defined
as the degree to which individuals have the capacity to obtain,
process and understand basic health information and services
needed to make appropriate health decisions [10]. Health lit-
eracy includes a range of skills such as numeracy and reading;
in a study assessing the readability of 345 patient information
booklets available in general practices, it was found that only
24% were written at the recommended reading level for the
general population (Felsch Kincaid Grade 6, equivalent to
reading age 10–11) [8, 11]. Furthermore, a sample of 64 UK
health information sources were found to be too complex
(based on assessment by the English National Qualifications
Framework), for 43% of the population to understand [9].
This rose to 61% if the information required numeracy skills
in addition to interpretation of text [12]. This mismatch be-
tween complexity of information and health literacy impacts
on access to healthcare and affects health outcomes. In osteo-
porosis, the language used to describe the condition is likely to
be important; the term osteoporosis itself is often misunder-
stood and a systematic review of patient information needs
reported uncertainty and confusion in areas relating to the
nature of the condition, medication and controllability [13].
The review further suggested the need for research into opti-
mum explanations of osteoporosis and the promotion of clear
messages that avoid ambiguity [13].
The ‘Improving uptake of Fracture Prevention drug treat-
ments (iFraP) study’ aims to address some of these issues, by
developing a decision tool, training package and information
resources to ensure consistent, accurate, understandable infor-
mation provision relating to osteoporosis and its drug
treatment. Our aim for this study was to inform the iFraP
intervention, by identifying commonly accessed patient infor-
mation resources, and within these resources, identifying fre-
quently used phrases and descriptors using a descriptive the-
matic analysis [14]. Additionally, we aimed to describe the
readability and quality of these resources. We sought stake-
holder views on quality (including accuracy and language
used) to make recommendations for improvement.
Methods
An overview of the methods is shown in Fig. 1.
Identification
We aimed to identify a purposive sample that would include
sufficient diversity, would be large enough for meaningful
analysis, and that would represent the majority of resources
used in primary and secondary care. Our purposive sampling
approach was informed by the methods of previous research
investigating content of patient information booklets in oste-
oarthritis [15]. Patient information resources were selected on
the basis that they were easily available either on the internet,
through patient organisations or in osteoporosis clinics. We
included webpages, booklets and videos, if transcripts were
available, for analysis. First, two clinical authors (ZP,
Consultant Rheumatologist and Clinical Lead for osteoporosis
service and AH, Specialist Registrar in Rheumatology) iden-
tified providers and resources of patient information common-
ly recommended to patients in primary and secondary care
that were expected to be identified in the search (informed
by the methods of Misra et al. [16]). A google search using
the term ‘osteoporosis’ was conducted on 20th December
2019 with hits being screened for UK specific patient infor-
mation. Inclusion was dependent on resources being from
three different types of provider: healthcare providers; chari-
table, voluntary or patient organisations; and the medical pro-
fession. Hits were reviewed sequentially until we had repre-
sentation from all three types of provider and the inclusion of
providers/resources preidentified by clinical authors [16].
Data extraction
In line with our study aims, we focused our investigation on
information related to describing the condition and drug treat-
ment. For each resource selected, text was extracted into
Microsoft® Word documents. Video transcripts and booklets
were extracted in their entirety. Text from webpages was ex-
tracted from sections on the webpage relating to descriptions of
osteoporosis and descriptions of osteoporosis drug treatment.
Text relating to lifestyle management and fracture management
was not included, as they were deemed outside of the scope of
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this study. Where websites contained information on osteopo-
rosis drugs and the condition in more than two webpages, two
authors (ZP and FCM) agreed which text to include through
discussion and recorded the decisions made on inclusion.
Quality assessment
Quality assessment comprised a readability score and a quality
checklist derived from patient information quality standards.
The readability scores were calculated utilising the Flesch
Reading Ease (FRE) and Flesch–Kincaid Grade Level
(FKGL) ‘Readability’ function in Microsoft® Word 2007.
Together, these scores provide a comprehensive picture of
patient information readability, in line with previous method-
ology [8]. The FRE assesses text on a 100-point scale [17],
with a high score indicating the document is easier to read.
The FKGL assesses the text based on the US school grade
level [18]. In contrast to the FRE, the lower the FKGL score,
the easier it is to understand.
Readability was calculated in Microsoft® Word for sec-
tions on osteoporosis and osteoporosis drug management sep-
arately. Readability of drug management was separated as it
has been shown previously to be more complex than descrip-
tive, condition-specific information [19]. Readability was cal-
culated from an average of three sections of text, each 100
words, following the methods of Protheroe et al. [8].
Sections of text were taken from the start, middle and end of
extracted text (avoiding contact details). The threshold of ac-
ceptable readability was set at a FRE score of > 60 and FKGL
of < 6 (suggesting a reading age of approximately 11), based
on the 2011 Skills for Life Survey and the recommended level
for provision of medical information [11].
In order to evaluate the quality of patient information, we
utilised a modified version of the International Patient
Decision Aid Standards (m-IPDAS). This scale has beenmod-
ified to measure the quality of patient information resources,
mapped against information quality standards attending to is-
sues of balance and bias [20]. The m-IPDAS scale determines
the quality based on eight areas: structure and layout, state-
ment of aims, information reliability, information about treat-
ment options, support provided to patients to make appropri-
ate decisions, disclosures of conflicts of interest, accurate in-
formation and probabilities of treatment outcomes [20]. We
included one additional question relating to the balance of
presentation of benefits and risks, which was derived from
an IPDAS update in 2009 [21]. In line with our study aim,
we considered treatment options as drug treatments for the
purpose of this exercise. An instruction sheet for completing
the m-IPDAS was formulated to clarify the questions and was
piloted with three reviews (FCM and LB or CG). The m-
IPDAS and instruction sheet are available in the supplemen-
tary materials (Supplementary Tables 1 and 2 respectively).
Pairs of researchers (FCM and LB or CG) assessed data ex-
tracted on the condition of osteoporosis and osteoporosis drug
treatments for each resource against the m-IPDAS criteria in-
dependently and referred to the original resource if required.
Disagreements were resolved through a fourth reviewer (ZP).
A total score out of 33 and a percentage was then calculated.
Descriptive/deductive thematic analysis
The extracted data was initially deductively coded; deduc-
tive coding means that a predefined list of codes are
assigned, as opposed to inductive coding where themes
Fig. 1 Overview of methods
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emerge from the data [14]. The five domains of Leventhal’s
Common-Sense Model of Disease were used as a deductive
coding framework [22] to ensure that analysis was theoret-
ically driven by the domains of illness perceptions which
influence coping strategies, and health behaviours, includ-
ing adherence to medication [23]. The five domains are
identity—the label or name given to the condition and as-
sociated symptoms; cause—individualistic ideas about the
apparent cause of the condition; timeline—beliefs about
how long the condition might last; consequences—beliefs
about the consequences of the condition and physical, men-
tal and social sequelae; controllability—beliefs about
whether the condition can be cured or kept under control
and the degree to which the individual plays a part in achiev-
ing this. The use of this model as a coding framework pro-
vides analytical focus on the description of osteoporosis in
the identified patient information resources, reflecting the
research question [24]. An additional round of inductive
coding (meaning that codes identified from the data, rather
than a pre-existing coding framework [14]) was conducted
to identify subthemes within each domain. In total, the ex-
tracted data underwent three rounds of coding by two inde-
pendent authors (CG or FCM, both novice qualitative re-
searchers but with clinical knowledge of osteoporosis); after
each round, coding was discussed with ZP, an experienced
qualitative researcher, and refined. ZP and FCM then agreed
a final coding framework which was systematically
reapplied across the extracted data by FCM and ZP.
Stakeholder views and generation of
recommendations
Expert members of the stakeholder group were recruited
through personal networks and the Royal Osteoporosis
Society (ROS), whilst patient members were recruited through
the Keele University School of Primary, Community and
Social Care research users group and included (n = 12, 3 males
and 9 females):
& Two ROS representatives
& Two GPs (one with health literacy expertise)
& Two hospital doctor specialists representing metabolic
bone, and rheumatology
& Two osteoporosis specialist nurses
& One physiotherapist
& Two patients with osteoporosis
& One patient and public involvement and engagement
(PPIE) support worker
An additional six members of the iFraP study team were
also present. Stakeholders were presented with the informa-
tion providers, and extracted phrases and words from each of
the five domains were presented to a stakeholder group to
identify any inaccurate or contradictory terms/advice and dis-
cuss optimal language, with the aim to develop recommenda-
tions for describing osteoporosis and its drug treatment.
Recommendations for improving patient information were
drafted by three authors, based on findings from the quality
assessment and stakeholder comments and reviewed by public
contributors.
Results
Nine patient information resources were identified from 6
providers: the NHS (a webpage and video) [25, 26]; three
chari t ies (ROS (formally known as the National
Osteoporosis Society), Versus Arthritis (VA) (formally
known as Arthritis Research UK) and Age UK—three
webpages and two pdf booklets) [27–31]; one doctor-led
webpage (Patient.info) [32] and one private healthcare
provider webpage (BUPA) [33]. The sample size of nine
was felt to be adequate by authors and stakeholders,
representing the majority of UK information providers in pri-
mary and secondary care, and being similar to previous stud-
ies in this area [15, 16].
Two resources contained all information on osteoporosis
and osteoporosis drugs on a single webpage, and this webpage
was extracted in entirety (BUPA and Age UK) [31, 33]. Three
websites had a main ‘osteoporosis’ webpage, with a second
linked webpage containing drug treatment information, both
of which were extracted in entirety (NHS webpage, VA
webpage and Patient.info) [26, 27, 32]. One website (ROS)
[30] contained relevant information on more than two
webpages; details of decision-making on information to ex-
tract for this site are available in supplementary infor-
mation Table 3. Video transcripts and booklets were
extracted in their entirety. A summary of the included
resources is shown in Table 1.
Quality: readability
Readability results are summarised in Table 2. Five of the nine
resources included less than 300 words relating to osteoporot-
ic drugs therefore it was only possible to calculate a single
readability score rather than a mean of 3 areas. None of the
resources scored within the acceptable range on both the FRE
and FKGL scales (> 60 and < 6 respectively). The information
on osteoporosis on the ROS webpage met an acceptable FRE
score, and the transcript of the information on osteoporosis
drugs from the NHS video met an acceptable FRE score. No
other resources met any criteria for readability for information
on the condition osteoporosis or osteoporosis drug treatment.
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Quality: m-IPDAS checklist assessment
The total m-IPDAS scores of individual resources ranged
from 21.2 to 63.6% and are detailed in Table 3. The highest
scoring resource was the National Osteoporosis Society
(NOS) booklet [29] scoring 21/33 (63.6%), followed by the
BUPA webpage [33] and Arthritis Research UK (ARUK)
booklet [28], each scoring 20/33 (60.6%). The NHS video
[25] scored the lowest (7/33 (21.2%)) and Age UK [31] sec-
ond lowest (13/33 (39.4%)).
The domains with the lowest scores were accuracy, proba-
bility, decision-making and conflicts of interest. Only 2/9
(22%) reported the source of the evidence quoted, and no
resource discussed event rates or probabilities when
discussing osteoporosis drug benefits and harms. Few re-
sources (3/9, 33%) recognised explicitly that the reader might
be making a decision about drug treatment, and only 2/9
(22%) helped the reader to identify the physical, social and
psychological consequences of untreated osteoporosis to aid
in this process, while only one included content to help the
reader think about their priorities and motivations. Four re-
sources provided information on the authors of the informa-
tion, and neither of the two privately owned resources stated
their funding source. Scores were highest in the domains re-
lating to content, usability and unbiased, structure and layout
and reliability, although these domains all included individual
items which scored low. For example, while most resources
included an explanation of purpose and content, none
Table 1 Summary of included patient information resources
Publisher Media Provider type Title Word count*
Age UK [31] Webpage Charity Osteoporosis 1058
Arthritis Research UK (ARUK) [28] Leaflet Charity Osteoporosis 6661
BUPA [33] Webpage Private sector Osteoporosis 3067
National Health Service (NHS) [26] Webpage Healthcare Osteoporosis 6265
NHS [25] Video Healthcare Osteoporosis Video 718
National Osteoporosis Society (NOS) [29] Leaflet Charity All about Osteoporosis and Bone health 23,612
Patient-info [32] Webpage Doctor led Osteoporosis 5202
Royal Osteoporosis Society (ROS)† [30] Webpage Charity Understanding Osteoporosis 6913
Versus Arthritis (VA)‡ [27] Webpage Charity Osteoporosis 3484
*Word count of extracted data
† Formally National Osteoporosis Society
‡ Formally Arthritis Research UK
Table 2 Readability results
Resource Readability of information describing
osteoporosis
Readability of information describing
osteoporosis drugs
FRE mean (range) FKGL mean (range) FRE mean (range) FKGL mean (range)
Age UK-W 59.13 (44.0–69.2) 8.27 (6.5–9.4) 34.1† 11.2†
ARUK-L 57.27 (53.4–60.6) 8.80 (7.9–9.9) 55.80 (45.6–70.7) 9.10 (6.7–11.0)
BUPA-W 53.57 (48.0–63.8) 9.33 (8.4–10.2) 45.9† 9.6†
NHS-W 56.53 (47.8–61.6) 9.30 (7.8–10.4) 50.00 (44.7–57.6) 9.53 (8.2–10.8)
NHS-V 55.37 (51.7–60.7) 9.57 (7.7–10.7) 68.9* 6.3†
NOS-L 48.20 (31.4–57.4) 12.80 (10.3–17.2) 52.13 (34.7–73.1) 10.93 (6.1–15.4)
Patient-info-W 57.03 (50.6–64.9) 8.20 (7.0–9.0) 51.97 (48.2–58.3) 9.73 (8.6–10.8)
ROS-W 62.07 (49.7–71.8)* 8.00 (7.1–9.6) 57.9† 8.4†
VA-W 50.97 (43.4–58.8) 10.80 (9.3–11.6) 50.1† 10.5†
* Indicates a score within acceptable limits (FRE > 60, FKGL < 6)
† Indicates result from single assessment, not mean, due to insufficient text for 3 assessments.






























































































































































































































































































































































































































































































































































































































































































































































































































































explicitly included a statement of who the information was
targeted at. Although resources noted the benefits (8/9,
88%) and risks (5/9, 55%) of osteoporosis drugs, only two
resources presented these in equal detail (22%). While
criteria relating to the description of the health condition
and its natural course were met in all resources, in the re-
sources that discussed drug treatment, five included discus-
sion of the procedures for taking treatment. The use of con-
sistent design and layout as well as information aids and em-
phasis, such as bullet points, noted in 7/9 (77%) resources. In
those that used diagrams (5/9, 55%), one did not provide any
labels. All resources provided detail on further information,
with 7/9 (77%) providing a date of publication.
Descriptive thematic analysis and stakeholder views
Thirteen individual subthemes were identified relating to the
five domains of Leventhal’s Common-Sense Model; identity,
cause, timeline, consequence and controllability (Fig. 2).
Keywords and phrases from nine of these subthemes were
discussed with the stakeholder group. The stakeholder group
confirmed that the most commonly used resources had been
included. A summary of the keywords and phrases identified
within each domain and subtheme, is shown in Table 4, and
described below. Key findings from the stakeholder discus-
sion are presented alongside the thematic analysis results, to
aid flow and reduce duplication of reporting.
Identity
Subthemes were identified relating to descriptions of osteopo-
rosis, symptoms, fracture risk and explanation of bone density
results. Although most resources explained osteoporosis
meant bones were more likely to break more easily, descrip-
tive terms used to describe the bone varied with terms such as
‘spongy’ [27, 28], ‘weak’ [27, 33], ‘thin’ [28, 32] and ‘frag-
ile’. Some of these terms were noted by the stakeholder group
to be misleading (spongy) or liable to cause fear (fragile); the
term ‘weak’was preferred. Further, when resources used com-
parisons to ‘average’ to describe osteoporosis, such as
‘bone density is lower than average’ [33], this was
viewed as confusing, as ‘average’ was not defined.
One resource described ‘idiopathic’ and ‘established’ os-
teoporosis which was perceived by stakeholders as too
technical for lay information [29].
Statements regarding symptoms were frequently contradic-
tory. Osteoporosis was described to have either no symptoms
[31–33] or ‘often has no symptoms’ [27]. Following a state-
ment of no symptoms, one resource still went on to list ‘signs
that you can look out for’ [31]. Of the resources that
discussed general symptoms, [27, 28, 30–33] only two
made it clear that all symptoms and signs were a result
of indolent fractures [28, 30].
Fracture risk was described as risk or probability of break-
ing a bone over 10 years. Resources gave two different rea-
sons as to why your fracture risk would be calculated to either
inform treatment choices or inform the need for dual-energy
X-ray absorptiometry (DXA) scanning (a means of measuring
bone mineral density), with two resources mentioning both
[27, 28]. Patient.info states that fracture risk calculations are
used to ‘determine your risk of developing osteoporosis’
which was deemed misleading by the stakeholder group
[32]. The stakeholder group expressed the view that it was
important to explain that risk of fractures is influenced by a































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































range of factors other than bone density alone and ‘chance’
was viewed as a more understandable term than ‘risk’ or
‘probability’. Bone density was described as measuring
quantity and strength. The NOS booklet additionally
distinguished between density and strength, and why
having low bone density does not automatically signify
a reduction in strength [29].
Causes
Subthemes related to pathology and risk factors. Most
resources included a description of bone histopathology
including cortical and trabecular bone [27–29, 33], some
went further to describe the biochemistry and cellular
biology [27–29, 32, 33]; however, stakeholders noted
that not everyone would want to know what is going
on inside the bone, particularly when receiving informa-
tion immediately after diagnosis. They did suggest that,
for those people who were interested in biology, car-
toons or animation might be helpful in explaining the
cellular activity in simplified terms such as ‘bone nib-
blers’ vs ‘bone builders’. Risk factors were variably
described, but all resources mentioned common risk fac-
tors such as increasing age, steroids and early meno-
pause. Stakeholders felt it was important to note that
anyone can get osteoporosis, and that the causes are
often not found; this was deemed important to avoid
patients blaming themselves for poor lifestyle choices
which may not have caused their osteoporosis.
Timeline
Subthemes identified related to the timeline of osteopo-
rosis itself, duration of drug treatment and timing of
follow-up. Loss of bone density over time was generally
described as normal, however the term ‘progressive’
[31] was discussed as sounding severe and unmodifiable
by stakeholders. Preference for the terms ‘develops
slowly’ as used by the NHS website [26] was
expressed. Treatment duration was discussed in relation
to bisphosphonates, as would be expected, as these
drugs are associated with increased risks with longer
duration of treatment. Four resources indicated that
bisphosphonates took 6–12 months to work [26–28,
32]. Timing of follow up was specified in four re-
sources (3–5 years) [27–29, 32] and related to the pos-
sibility of a treatment break as ‘long-term treatment can
sometimes have side-effects’ [27, 28]. The VA webpage
outlined that the benefits of bisphosphonates are long
term and would not be lost during a treatment break
[27]. The NOS booklet also stated ‘some may continue
to have an effect for several years after treatment is











































































































































































































































































































































































































the risk of breaking a bone most effectively while you
are taking them’ and ‘when you stop treatment the ben-
efit will start to wear off’ [29].
Consequences
Subthemes identified related to consequences of osteoporosis
and side effects of medication. In terms of consequences of
osteoporosis, fractures were noted as sequels of both the con-
dition and nontreatment. Fractures were described as ‘fragility
fractures’ [26, 29, 32], ‘low-impact’ fractures [27] or fractures
being caused by minor accidents/events [29, 33]. The BUPA
webpage and NOS booklet were the only resources tomention
the psychosocial and physical consequences following a frac-
ture such as long-term disability and reduced life expectancy
[29, 33]. Stakeholders noted that life expectancy may not be
important to everyone, and that it would be better to
relate fracture consequences to things important to pa-
tients using more lay terminology relating to work,
hobbies and confidence.
In terms of side effects, osteonecrosis of the jaw (ONJ) and
atypical femur fractures were described as ‘less common’ but
‘more serious’ [27, 30, 32] or ‘rare’ [26, 27, 32].
The ROS website used statements such as ‘be reassured
that it’s unlikely you will experience any’ [30] in relation to
side effect risk, whilst Patient.info used phrases such as ‘if you
develop any symptoms….you should stop taking your tablets
and see your doctor’ [32]. Stakeholders noted that many of the
terms used to describe side effects may not be easy to
understand and suggested using more commonly
understood language, e.g. gullet instead of oesophagus.
Further, it was suggested that side-effect timelines be
noted, such as in the case of joint pain with
bisphosphonates which may be transient.
Controllability
Subthemes related to benefits of medication, and how to take
medication. Generally, there was little information on benefits
of drug treatment. Resources described benefits of bisphos-
phonate medication in terms bone strength, bone density and
fracture risk. However, terminology varied, with the benefits
described as ‘reduced risk {of fracture}’ [25, 26, 28, 34],
‘prevent’ {fractures and bone loss} [25, 27, 29, 31], ‘increase’
{bone strength} [27, 28], ‘slow’ {bone loss} [27, 28, 33].
Stakeholder discussions felt that terms relating to restoring,
renewing or returning bone mineral density (BMD) to normal
and preventing fracture were misleading. They recommended
the term ‘strengthen bone’ and description of ‘lowering the
chance of future fracture’. Medication was also noted by
stakeholders to give confidence—a psychosocial factor that
could be included as a benefit.
Instructions around medication were given to ‘ensure the
medication is effectively absorbed’, and that patients should
‘carefully follow the instructions’ [28] ‘even though you
won’t be able to feel whether it’s working’ [27]. The sources
gave a mixture of advice on instructions in relation to how
much water to drink, how long to avoid food and how long to
stay upright, with all resources suggesting more fluid or more
time upright than the Summary of Product Characteristics for
alendronic acid 70 mg, (which recommends one glass water
and minimum 30 min respectively [35]). The NOS booklet
added a tip to increase the likelihood of remembering to take
the weekly tablet; ‘the day your bins are emptied’ [29].
Discussion
Good quality patient information can educate, inform and em-
power patients, enabling them to partake in shared decision-
making regarding their conditions and support self-manage-
ment. However, materials need to be of high quality and com-
prehensible in their presentation, language and content.
Overall, this study found that patient information on osteopo-
rosis had highly variable quality and scored poorly on read-
ability assessments. The contradictions, inaccuracies and in-
consistencies identified are particularly troubling, specifically
relating to how symptoms are described, how to take
medication and the benefits of treatment. We have pro-
duced 12 practical recommendations addressing the gaps
identified by this study in order to support improve-
ments in osteoporosis information.
Using readability as part of an assessment of quality, our
findings suggest that all of the included online resources are
too complex for the majority of UK residents. All resources in
the current study scored above a grade 8 on the FKGL (except
the NHS video on information describing osteoporosis drugs),
which would exclude at least 43% of UK residents of
working age, from understanding the information [12],
and given, that health literacy declines with age [11]
may exclude an even greater proportion of the popula-
tion with, or at risk of osteoporosis.
Osteoporosis information resources are not alone in this, a
study that included over 300 patient information resources
available in doctors surgeries found that 75% were above
the average national reading level [8]. Other studies fo-
cusing on individual topics such as urological conditions
[36], trauma [37], and surgical reconstruction [38] have
found similar results, with the majority of resources
scoring above grade 8 on the FKGL.
The m-IPDAS quality assessment identified areas of weak-
ness across the resources evaluated. Notably, resources scored
poorly in the m-IPDAS domains of ‘accuracy’ and ‘probabil-
ities’, with both the stakeholder discussion and the m-IPDAS
highlighting an imbalance between the presentation of risks
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and benefits of bisphosphonates, in favour of the latter. This
difference may, to some extent, be influenced by negative
media on bisphosphonates [39]. Although benefits were
discussed in less detail, the claims of benefits were sometimes
misleading, suggesting fracture prevention and renewal of
bone in line with a range of other conditions such as which
has been described as overoptimistic [20]. Patients have pre-
viously expressed the desire to know the ‘full picture’; how-
ever, they want it presented in a balanced manner with a del-
icate and truthful assessment of the risks and benefits [20]. It is
also important patients have realistic expectations of treatment
benefit, as poor alignment between outcome and expectations
is likely to contribute to poor adherence. Research evidence
suggests the inclusion of event rates and outcome probabili-
ties, using simple frequencies, e.g. 1 in 100, as a mechanism to
facilitate balanced risk communication and shared decision-
making [40]. However, as evidenced by the m-IPDAS, re-
sources included event rates of fractures in general, but not
probabilities relating to osteoporosis or specific osteoporotic
fractures. To further ensure the relevance and appropriateness
of the information, resources should explicitly state who the
information was intended for. The m-IPDAS quality assess-
ment identified that none of the included online osteoporosis
resources provided such information. A disclosure of this kind
is particularly pertinent for osteoporosis drug treatment, as
drug information for females and males may differ, such as
in the case of drug licensing [41], and our public contributor
group also expressed the importance of stating whether re-
sources were generally relevant to both men and women.
Only two resources reference their evidence, as has previously
been seen in other information sources for other conditions,
with a high proportion failing to disclose their evidence
sources [5]. Disclosure of funding is also important, especially
for a subspeciality which has been heavily criticised for its
connections with the pharmaceutical industry [42].
Our thematic analysis revealed a range of different
descriptors for the condition; the term osteoporosis has
different meanings (e.g. low bone mineral density, pre-
vious fragility fracture), and these different representa-
tions may contribute to confusion, e.g. about the rela-
tionship with symptoms [43]. To address confusion and
inconsistency, the stakeholder group supported the use
of simplified, clear terminology and an avoidance of
complex science in their suggestions regarding osteopo-
rosis description, medication benefits and side effects.
Stakeholders suggested that the benefits of osteoporosis
drug treatment should be made relatable to patient’s
values, motivations and priorities, such as hobbies and
confidence levels. When highlighting risks, resources
should focus on the potential social, psychological and
physical consequences of not taking osteoporosis treat-
ment (e.g. care home admission, reduced independence),
as these factors scored low in the m-IPDAS quality
assessment. This information should be linked to the
benefits of treatment; previous research has highlighted
that people with osteoporosis did not understand the
purpose of drug treatment [13] and low perceived need
for treatment is associated with nonadherence [44].
Recommendations for improving patient information
about osteoporosis
General considerations:
1. Explicitly state the target audience for the information
2. Simplify language used, avoid technical language and en-
sure readability is appropriate
3. Cite sources of evidence
4. Cite sources of funding
When describing osteoporosis:
5. Use recommended terms, e.g. ‘weak bone’ and avoid
terms such as ‘spongy’ and ‘honeycomb’
6. Explain osteoporosis develops slowly and anyone can get
it
7. Avoid contradictory statements about absence or presence
of symptoms and ensure symptoms and signs are ex-
plained as caused by fractures
8. Include discussion of the physical, social and psycholog-
ical impact of osteoporotic fractures, but avoid descrip-
tions that may induce fear
9. Use labelled images or animations where possible, e.g. to
illustrate pathology
When describing osteoporosis drug treatment:
10. Balance the amount of information about benefits and
risks of drug treatment, and describe using probabilities
or simple event rates
11. Describe the benefits of treatment as strengthening bone
and lowering the chance of future fracture, and avoid
misleading terms such as ‘prevent’, ‘renew’ and ‘restore’
12. Provide accurate information about how to take
bisphosphonates, and how long for, and explain why
these procedures are important
Given the need for clear communication of the benefits
versus the risks of drug treatment is internationally recognised
as a priority area in improving osteoporosis management and
care [9, 45], we recommend that providers of osteoporosis
health care information assess their current resources against
these criteria to identify avenues for improvement that will
make patient information more accessible and readable.
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Furthermore, existing providers need to address any uncer-
tainty and confusion in areas relating to the nature of the
condition, medication, and controllability [13]. When produc-
ing new resources, we suggest providers utilise these recom-
mendations to check that they align accordingly to increase
consistency, and ensure high quality and readability of osteo-
porosis health information.
Strength and weaknesses
Multiple methods were utilised in this study to explore online
patient information about osteoporosis, including an in-depth
readability and quality assessment (utilising the m-IPDAS); a
descriptive thematic analysis informed by theory; and engage-
ment with a diverse stakeholder group consisting of experts,
clinicians and patients. Including the views of public contrib-
utors is essential in design and appraisal of patient information
to inform relevance, understanding and acceptability of infor-
mation [13, 20]. Each method contributed to a robust and
rounded understanding of the quality of osteoporosis patient
information, and we believe these methods would be of use to
study patient information about other subjects.
A number of limitations are worthy of mention. First, in-
formation about lifestyle was not included in this investiga-
tion, and therefore, the quality of information about
nonpharmacological management remains to be determined.
We focused upon the quality and readability of information
about osteoporosis and osteoporosis drug treatments to inform
the design of the iFraP intervention and also based on two of
the three top priorities in osteoporosis research: having easy
access to information and understanding further the safety and
benefit of osteoporosis drug treatment [2]. Second, readability
scores, utilised in this study as a quality indicator, have been
criticised for use in medical situations, as they cannot account
for necessary medical terms [8]. However, previous studies
have shown good reproducibility, correlationswith other read-
ability scales and have been previously utilised within a health
information context [11, 36, 37].
Third, it is likely that quality and readability assessments
were related to the length of the text included, and we did not
formally evaluate this relationship. For example, the video,
the shortest resource scored best on readability and worst on
m-IPDAS. The longest resource (NOS booklet), also scored
highest in the m-IPDAS. High scores in m-IPDAS did not
necessarily relate to quality overall, with a number of chal-
lenging or confusing textual descriptors identified by stake-
holders, emphasizing the value of the combined methods
used. Furthermore, we did make selections on which text to
include: some of the providers of information do provide a
wide range of resources and may have included relevant pa-
tient information or content in other resources or documents
that we did not include. However, where relevant e.g. disclo-
sure of funding, we did attempt to find information on the
source webpage. Finally, although visual elements (e.g. use
of images) are included within the IPDAS rating, our study
did not include a detailed evaluation of the style, layout or
format of resources, which remains in need of further study.
Conclusion
This study found that commonly accessed patient information
resources on osteoporosis were too complex for most of the
population and identified areas of weakness using a validated
quality measure. Inconsistencies and inaccuracies were noted
in the phrases used as well as terms that were difficult for
patients to understand. We have produced practical recom-
mendations for information providers to support improve-
ments in understanding, relevance, balance and bias, and to
address information gaps.
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